Daily Dose: Effect of Sotagliflozin on Heart Failure-Related Events

©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

Last week, we reported on a posthoc analysis of the SOLOIST-WHF trial published in JAAC: Heart Failure.

The study

Researchers identified 596 SOLOIST-WHF patients who received sotagliflozin on or before hospital discharge to explore the effect of sotagliflozin on risk of cardiovascular (CV) death or heart failure (HF)-related events (ie, hospitalization for heart failure [HHF] or urgent care visit) within 90 and 30 days of hospital admission.

The findings

• Among patients hospitalized for HF who began treatment with sotagliflozin before or at the time of discharge, the relative risk of CV mortality or HHF or need for urgent care at 90 days post-discharge was reduced by 46% and at 30 days by 51% compared to patients who received placebo.

• The risk of HF-related events among sotagliflozin-treated patients was significantly reduced by 48% and 52% during the 90- and 30-day postdischarge periods, respectively.

• All-cause death among sotagliflozin-treated patients vs those treated with placebo was reduced by 61% at 90 days.

Authors' commentary

"These findings are the first to demonstrate a decrease in mortality and HF events for a SGLT inhibitor treatment initiated during WHF hospitalization and underscore the benefits of early initiation of evidence-based HF therapy. These results suggest that dual inhibition of SGLT1 and SGLT2 is safe and may provide added benefit to patients with WHF."

Click here for more details.